Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

about

Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Item

http://www.wikidata.org/entity/Q38634826

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Reactivation of occult hepatit ...... isk assessment and prevention.

@en

type

Item

label

Reactivation of occult hepatit ...... isk assessment and prevention.

@en

prefLabel

Reactivation of occult hepatit ...... isk assessment and prevention.

@en

P1476

Reactivation of occult hepatit ...... isk assessment and prevention.

@en

P2093

Masaru Kato

http://www.w3.org/2001/XMLSchema#string

Tatsuya Atsumi

http://www.w3.org/2001/XMLSchema#string

P2860

Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks

Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient.

Toll-like receptor signaling inhibits hepatitis B virus replication in vivo.

Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.

CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection.

Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes.

Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.

Hepatitis B virus DNA contains a glucocorticoid-responsive element.

Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs

Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection.

P2888

s00296-015-3395-x

P304

635-641

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00296-015-3395-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1035527180

http://www.w3.org/2001/XMLSchema#string

P698

26573663

http://www.w3.org/2001/XMLSchema#string